

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Paul A. RENHOWE et al.  
Title: HETEROCYCLIC COMPOUNDS  
Prior Appl. No.: 10/452,786  
Filing Date: Submitted Herewith  
Examiner: Unknown  
Art Unit: Unknown

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Mail Stop PATENT APPLICATION  
Commissioner for Patents  
PO Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Applicants submit herewith on Form PTO-1449 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 10/452,786, filed June 02, 2003, and parent application Serial No. 09/943,382, filed August 30, 2001. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The USPTO has waived the requirement under 37 CFR 1.98(a)(2)(i) to submit copies of U.S. patents and U.S. patent application publications when citing and submitting an Information Disclosure Statements in a patent application filed after June 30, 2003, and in an international application that has entered the national stage under 37 USC §371 after June 30, 2003. Accordingly, copies of these types of documents are not being supplied in connection with this application. Reference is being made to Pre-OG Notice from Office of Patent Legal Administration dated July 25, 2003, *Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003.*

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

**RELEVANCE OF EACH DOCUMENT**

An English translation of the foreign-language document(s) is not readily available. However, an English language abstract of each of the foreign language document(s) was included with the references in the parent application.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-2350. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-2350.

Respectfully submitted,

Date April 14, 2004

By Bernard P. Friedrichsen

FOLEY & LARDNER LLP  
Customer Number:

**23524**

PATENT TRADEMARK OFFICE

Telephone: (608) 258-4281

Facsimile: (608) 258-4258

Bernard P. Friedrichsen  
Attorney for Applicant  
Registration No. 44,689

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 072121-0389		SERIAL NO.	
<b>INFORMATION DISCLOSURE CITATION</b>  Date filed: April 14, 2004 <i>(Use several sheets if necessary)</i>				APPLICANT Paul A. Renhowe et al.			
				FILING DATE Submitted Herewith		GROUP ART UNIT Unknown	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
		4,882,342	Nov. 21, 1989	Von der Saal et al.			
		5,073,492	Dec. 17, 1991	Chen et al.			
		5,414,088	May 9, 1995	Von der Saal et al.			
		5,585,380	Dec. 17, 1996	Bianco et al.			
		5,646,153	Jul. 8, 1997	Spada et al.			
		5,710,158	Jan. 20, 1998	Myers et al.			
		5,763,441	Jun. 9, 1998	App et al.			
<b>FOREIGN PATENT DOCUMENTS</b>							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
		2363459	Jun. 26, 1975	Germany			
		DE 3634066 A1	July 10, 1986	Germany			
		19841985	Mar. 9, 2000	Germany			
		0 290 153	Nov. 9, 1998	Europe			
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
		Aprelikova, O., et al., "FLT4, a novel Class III Receptor Tyrosine Kinase in chromosome 5q33-qter1," <i>Cancer Res.</i> , Vol. 52, pp. 746-748, February 1, 1992, published by The American Association for Cancer Research, Stanford University Libraries' High Wire Press, California, United States of America.					
		Carmeliet, P. et al., "Angiogenesis in Cancer and Other Diseases," <i>Nature</i> , 407, pp. 249-257 (2000).					
		Connolly, D., et al., "Human Vascular Permeability Factor," <i>J. Biol. Chem.</i> , Vol. 264, pp. 20017-20024, 1989, published by The American Society For Biochemistry and Molecular Biology, Inc., Stanford University Libraries' High Wire Press, California, United States of America.					
		Connolly, D., et al., "Tumor Vascular Permeability Factor Stimulates Endothelial Cell Growth and Angiogenesis," <i>J. Clin. Invest.</i> , Vol. 84, pp. 1470-1478, November, 1989, published by The American Society for Clinical Investigation, Inc., Stanford University Libraries' High Wire Press, California, United States of America.					
		DeVries, C., et al., "The fms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," <i>Science</i> , Vol. 255, pp. 989-991, February 21, 1992, published by The American Society for the Advancement of Science, Stanford University Libraries' High Wire Press, California, United States of America.					
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>			
* <b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							



Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 072121-0389		SERIAL NO.		
<b>INFORMATION DISCLOSURE CITATION</b>  <i>(Use several sheets if necessary)</i>				APPLICANT Paul A. Renhowe et al.				
				FILING DATE Submitted Herewith		GROUP ART UNIT Unknown		
<b>FOREIGN PATENT DOCUMENTS</b>								
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
		0 509 717	Apr. 10, 1992	Europe				
		0 508 800	Oct. 14, 1992	Europe				
		0 747 771	Dec. 11, 1996	Europe				
		0 797 376	Sep. 24, 1997	Europe				
		1 086 705	Mar. 28, 2001	Europe				
		6-9952	Jan. 18, 1994	Japan				
		7-43896	Feb. 14, 1995	Japan				
		8-29973	Feb. 2, 1996	Japan				
		63-258903	Oct. 26, 1998	Japan				
		92/18483	Oct. 29, 1992	WO				
		92/20642	Nov. 26, 1992	WO				
		95/15758	Jun. 15, 1995	WO				
		95/18801	Jul. 13, 1995	WO				
		97/03069	Jan. 30, 1997	WO				
		97/34876	Sep. 25, 1997	WO				
		97/48694	Dec. 24, 1997	WO				
		98/13350	Apr. 2, 1998	WO				
		99/10349	Mar. 4, 1999	WO				
		99/50263	Oct. 7, 1999	WO				
		99/65897	Dec. 23, 1999	WO				
		00/27379	May 18, 2000	WO				
		01/02369	Jan. 11, 2001	WO				
		01/29025	Apr. 26, 2001	WO				
		01/28993	Apr. 26, 2001	WO				
		01/52904	Jul. 26, 2001	WO				
		01/55114	Aug. 2, 2001	WO				
		01/62251	Aug. 30, 2001	WO				
		01/62252	Aug. 30, 2001	WO				
		02/32861	Apr. 25, 2002	WO				

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 072121-0389	SERIAL NO.
<b>INFORMATION DISCLOSURE CITATION</b>  (Use several sheets if necessary)		APPLICANT Paul A. Renhowe et al.	
		FILING DATE Submitted Herewith	GROUP ART UNIT Unknown
		<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>	
		Ferrara, N., et al., "The Biology of Vascular Endothelial Growth Factor," <i>Endocrinol. Rev.</i> , Vol. 18, No. 1, pp. 4-25, 1997, published by The Endocrine Society, Stanford University Libraries' High Wire Press, California, United States of America.	
		Folkman, J., "Fighting Cancer by Attacking Its Blood Supply," <i>Scientific American</i> , Vol. 275, pp. 150-154, September, 1996, published by Scientific American, Inc., New York, New York, United States of America.	
		Hennequin, L. F., et al., "Design and Structure - Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors," <i>J. Med. Chem.</i> , Vol. 42, No. 26, pp. 5369-5389, 1999; published by American Chemical Society, Washington, D.C.	
		Leung, D., et al., "Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen," <i>Science</i> , Vol. 246, pp. 1306-1309, December 8, 1989, published by The American Society for the Advancement of Science, Stanford University Libraries' High Wire Press, California, United States of America.	
		Lymboussaki, A., "Vascular endothelial growth factors and their receptors in embryos, adults, and in tumors," Academic Dissertation, University of Helsinki, Molecular/Cancer Biology Laboratory and Department of Pathology, Haartman Institute, 1999.	
		Maguire, M.P., et al., "A New Series of PDGF Receptor Tyrosine Kinase Inhibitors: 3-Substituted Quinoline Derivatives," <i>J. Med. Chem.</i> , Vol. 37, No. 14, pp. 2129-2137, 1994; published by American Chemical Society, Washington, D.C.	
		Matei, S., et al., "Condensation of ethyl 2-benzimidazoleacetate with carbonyl compounds," <i>Rev. Chim.</i> , Vol. 33, No. 6, pp. 527-530, 1989, published by the Central Institute of Chemistry, Bucharest, Romania.	
		Mustonen, T., et al., "Endothelial Receptor Tyrosine Kinases Involved in Angiogenesis," <i>J. Cell Biology</i> , Vol. 129, No. 4, pp. 895-898, May, 1995, published by The Rockefeller University Press, New York, New York, United States of America.	
		Plouet, J., et al., "Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells," <i>EMBO J.</i> , Vol. 8, No. 12, pp. 3801-3806, 1989, published by IRL Press.	
		Quinn, T., et al., "Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 90, pp. 7533-7537, August, 1993.	
		Shibuya, M., et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family," <i>Oncogene</i> , Vol. 5, pp. 519-524, 1990, published by Macmillan Press Ltd., Stockton Press Company, Great Britain.	
		Stover, D. R., "Recent advances in protein kinase inhibition: Current molecular scaffolds used for inhibitor synthesis," <i>Current Opinion in Drug Discovery &amp; Development</i> , Vol. 2, No. 4, pp. 274-285, 1999; published by PharmaPress Ltd., London, United Kingdom.	
		Terman, B., et al., "Identification of a new endothelial cell growth factor receptor tyrosine kinase," <i>Oncogene</i> , Vol. 6, pp. 1677-1683, 1991, published by Macmillan Press Ltd., Stockton Press Company, Great Britain.	
		Ukrainets, I., "Effective Synthesis of 3-(Benzimidazol-2-yl)-4-Hydroxy-2-Oxo-1,2-Dihydroquinolines," <i>Tet. Lett.</i> , Vol. 36, No. 42, pp. 7747-7748, 1995, published by Elsevier Science Ltd., Great Britain.	
		Ukrainets, I., et al., "2-Carbethoxymethyl-4H-3,1-Benzoxazin-4-One. 3.*Condensation of o-Phenylenediamine," pp. 198-200, translated from <i>Khimiya Geterotsiklicheskikh Soedinii</i> , No. 2, pp. 239-241, February, 1992, published by Plenum Publ. Corp., London, Great Britain.	

